DOUGLAS Group vs Revolution Beauty

DOUGLAS Group reports third quarter results in line with expectations and confirms full-year guidance

Q3 sales declined 2.0% to 987.8 million euros, adjusted EBITDA margin 12.9%; full-year guidance confirmed for FY 2025/2026.

DOUGLAS Group publishes 9M FY 2025/26 Interim Statement and Results Presentation

New interim statement for the first nine months of fiscal year 2025/26, along with a results presentation and a webcast recording of the financial results.

Douglas shifts to digital after weak core markets

Douglas Group reported weaker Q3 2025/26 results as demand softened in key Western European markets and price competition intensified. April–June revenue fell 2.0% to €987.8m and adjusted EBITDA declined 19.4% to €127.5m (margin 12.9%). Nine-month revenue rose slightly (+0.5% to €3.61bn) while adjusted EBITDA fell 9.0% to €577.3m. The company confirmed its full-year guidance for 2025/26 and said it will increase its digital focus, review and rationalize its store network, expand exclusive brands and cross-channel services, and standardize group-wide structures. E‑commerce trends vary regionally (double-digit growth in parts of Southern/Central Europe and France but declines in DACHNL), Retail Media revenue grew 24%, and Click & Collect Express usage rose. Douglas plans to present a strategy update (“Let it Bloom”) in Q4 2026 emphasizing technology, e‑commerce, cross‑channel services, and a more profitable store footprint.

• Douglas Group Q3 (Apr–Jun 2025/26) revenue: €987.8 million, down 2.0%.
• Adjusted EBITDA in Q3 fell 19.4% to €127.5 million; adjusted EBITDA margin: 12.9%.
• Nine-month revenue increased 0.5% to €3.61 billion; nine-month adjusted EBITDA decreased 9.0% to €577.3 million (margin 16.0%).

8-K Financial Filing Analysis for Revolution Beauty (2026-08-19)

On August 17, 2026, the Compensation Committee of Revelation Biosciences, Inc. approved material restricted stock grants to executive leadership under its Amended and Restated 2021 Equity Incentive Plan. Chief Executive Officer James Rolke received 208,076 restricted shares, and Chief Financial Officer Chester S. Zygmont, III was granted 208,073 restricted shares. The equity awards are structured to vest across four equal 25% tranches linked to either reaching market capitalization hurdles of $30 million, $60 million, $90 million, and $120 million for 20 consecutive trading days, or time-based vesting at the two-year and four-year marks. The package aligns executive compensation with aggressive market valuation targets while providing retention security.

• CEO James Rolke and CFO Chester S. Zygmont, III were granted 208,076 and 208,073 restricted shares, respectively, under the 2021 Equity Incentive Plan.
• Awards vest in four equal 25% tranches upon reaching market capitalization thresholds of $30M, $60M, $90M, and $120M sustained over 20 consecutive trading days, or alternatively at 2-year (first two tranches) and 4-year (final two tranches) time intervals.
• Grants include standard accelerated vesting protections upon a Change in Control or qualified involuntary termination events.